← Retour au Screener

Sector: Santé
Open in Terminal → RDNTLive chart · Key metrics · News · Smart money

RadNet, Inc.

RDNT Mid Cap

Healthcare · Diagnostics & Research

Mis à jour: Jun 18, 2026, 22:21 UTC

46,90 €
+1.74% aujourd'hui
52W: 44,30 € – 74,91 €
52W Low: 44,30 € Position: 8.5% 52W High: 74,91 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
56.97x
P/E prévisionnel
P/S Ratio
1.97x
Cours/Ventes
EV/EBITDA
24.49x
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
3,7 Md €
Capitalisation boursière
Croissance du CA
22.1%
Croissance du CA sur un an
Marge bénéficiaire
-0.66%
Marge nette
ROE
1.77%
Rentabilité des capitaux propres
Beta
1.39
Sensibilité au marché
Positions vendeuses
13.8%
% du flottant vendu à découvert
Volume moyen
809,814
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
8 analysts
Avg. Price Target
78,32 €
+67.01% upside
Target Range
56,72 € – 87,27 €

About the Company

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 11,000 Exchange: NGM

RadNet, Inc. en bref

RadNet, Inc. (RDNT) is currently trading at 46,90 € with a market capitalization of 3,7 Md €. The 52-week range spans from 44,30 € to 74,91 €; the current price is 37.4% below the yearly high. Year-over-year revenue growth stands at +22.1%.

💰 Dividende

RadNet, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent RadNet, Inc. (RDNT) au consensus : Achat Fort. L'objectif de cours moyen est de 78,32 €, soit un potentiel de +67.01% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 56,72 € à 87,27 €.

RadNet, Inc. : la thèse d'investissement en détail

RadNet, Inc. (RDNT) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 22.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Strong Buy with an average price target implying roughly 67.01% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 13.8% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

With a PEG ratio of 0.96, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

  • The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
  • The analyst consensus price target implies 67.01% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Forte croissance du CA de 22.1% sur un an
  • Consensus des analystes : Strong Buy
  • Free cash flow positif
Points faibles
  • Actuellement non rentable
  • Positions vendeuses élevées (13.8%)

Aperçu technique

MM 50 jours
48,87 €
-4.04% vs. cours
MM 200 jours
59,70 €
-21.44% vs. cours
Sous le plus haut 52s
−37.4%
74,91 €
Au-dessus du plus bas 52s
+5.9%
44,30 €

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

Risque de marché (Bêta)
1.39 · Élevé
Évolue plus que le marché global
Positions vendeuses
13.8% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
143 · Élevé
Dette totale / capitaux propres

The data points to market-like volatility, elevated short interest (13.8%), higher leverage relative to equity.

Trading Data

50-Day MA: 48,87 €
200-Day MA: 59,70 €
Volume: 2,466,547
Avg. Volume: 809,814
Short Ratio: 10.88
P/B Ratio: 3.82x
Debt/Equity: 143x
Free Cash Flow: 166 M €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy RadNet, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut